Sargowo D, Prasetya I, Ashriyah R, Setyawati I, Andri W. T, Heriansyah T. Anti Inflammation and Anti Oxidant Effect of Active Agent Polysaccharide Peptide (Ganoderma Lucidum) in Preventing Atherosclerotic Diseases. Biomed Pharmacol J 2015;8(1)
Manuscript received on :--
Manuscript accepted on :--
Published online on: 15-11-2015
How to Cite    |   Publication History
Views Views: (Visited 327 times, 1 visits today)    PDF Downloads: 305
Anti Inflammation and Anti Oxidant Effect of Active Agent Polysaccharide Peptide (Ganoderma Lucidum) in Preventing Atherosclerotic Diseases

Djanggan Sargowo1,4, Indra Prasetya1, Ria Ashriyah1, Ira Setyawati1, W Titin Andri2, Teuku Heriansyah3

1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Brawijaya University / Dr. Saiful Anwar Hospital, Malang 2Department of Nursery, Faculty of Medicine, Brawijaya University, Malang 3Department of Cardiology and Vascular Medicine, Faculty of Medicine, Syiah Kuala University / Dr. Zainoel Abidin Hospital, Banda Aceh 4Department of Internal Medicine, Faculty of Medicine, Brawijaya University / Dr. Saiful Anwar Hospital, Malang. Jaksa Agung Suprapto Street, no. 2, Malang 65111, Indonesia *Corresponding author E-mail: djanggan@yahoo.com

DOI : http://dx.doi.org/10.13005/bpj/578

Abstract:

This study was aimed to evaluate anti-inflammatory and antioxidant effect of polysaccharide peptide (PsP) from Ganoderma lucidum in atherosclerosis. The atherosclerotic rats were randomly divided into four groups (5 rats each group) : atherosclerotic model with high-fat diet, low dose PsP treated group (50 mg/kgBW), medium dose PsP treated group (150 mg/kgBW), high dose PsP treated group (300 mg/kgBW), with normal mice used as a control group. Parameters measured were the level of MDA, SOD, IL - 6 , IL - 10, hsCRP, TNF - α, lipid profile and foam cell. After PsP therapy for 5 weeks, the levels of MDA (p=0.01), hsCRP (p=0.018) in rats model of atherosclerosis decrease significantly. PsP can reduce levels of IL - 6 (p=0.933) and increase levels of SOD (p=0.28) descriptively at PsP doses 150 mg/kgBW. While the levels of TNF-α (p=0.894) and IL-10 (p=0.98) was not affected by administration of PsP. PsP improve the lipid profile by increasing HDL (p=0.002) and lowering total cholesterol (p=0.04). The formation of foam cells (p=0.024) as a marker of atherogenesis significantly decreased by administration of PsP. PSP can be useful to reduce inflammatory processes and oxidative stress to prevent atherogenesis .

Keywords:

polysaccharide peptide (Ganoderma lucidum); anti-inflammation; anti oxidant; cardiovascular disease; atherosclerosis

Download this article as: 
Copy the following to cite this article:

Sargowo D, Prasetya I, Ashriyah R, Setyawati I, Andri W. T, Heriansyah T. Anti Inflammation and Anti Oxidant Effect of Active Agent Polysaccharide Peptide (Ganoderma Lucidum) in Preventing Atherosclerotic Diseases. Biomed Pharmacol J 2015;8(1)

Copy the following to cite this URL:

Sargowo D, Prasetya I, Ashriyah R, Setyawati I, Andri W. T, Heriansyah T. Anti Inflammation and Anti Oxidant Effect of Active Agent Polysaccharide Peptide (Ganoderma Lucidum) in Preventing Atherosclerotic Diseases. Biomed Pharmacol J 2015;8(1). Available from: http://biomedpharmajournal.org/?p=782

Introduction

Coronary artery disease (CAD) is one of the leading causes of mortality in the world. It is shown that 48 % of deaths in the world related with non-infectious diseases, is cardiovascular disease. In 2008, 17.3 million people died from cardiovascular disease, 7.3 million due to heart attack and 6.2 million due to stroke (Go AS, et al, 2014). Atherosclerosis is caused by inflammation or chronic inflammation produced by macrophages, polymorfonuclear cells, and his cytokines (Sprague A and Khalil R, 2009).

It has recently been developed herbal medicine as complementary therapy on CAD patients including Ganoderma lucidum. Ganoderma lucidum is a favorite ingredient in traditional oriental medicine for centuries. Several studies have shown Ganoderma Lucidum extract useful on CAD, clinically improving clinical complaints, lowering total serum cholesterol, improves ECG and blood pressure (Yihuai G, et al, 2004). In addition the study also showed benefits in Scandinavia, extracts of the fungus Saccharomyces cerevisiae wall containing β-glucan given to patients undergoing CABG, which decreases the inflammatory response and protect the heart from reperfusion injury (Xu Z, et al, 2011). But only limited study focus in effect of Ganoderma lucidum in chronic inflammation and oxidative stress in atherogenesis.

In this study, the authors aims to prove the effect of extracts of Ganoderma lucidum, polysaccharides peptide (PsP) that contains bioactive β-D-glucan on markers of chronic inflammation and oxidative stress in rat given High Fat Diet (HFD).

Methods

This study was designed using the experimental method in rats to determine the effect of PsP for the treatment of chronic inflammation process. This research was conducted at the Central Laboratory of Life Sciences Brawijaya (LSIH) University of Brawijaya, Malang.

Experimental animals in this study were rats (rattus norvegicus) obtained from CV Gamma Scientific Biolab, Malang. Inclusion criteria were male rats, approximately 3 months of age, weight about 150-200 grams, healthy condition and no anatomical abnormalities. While the exclusion criteria are rats had diarrhea during the study period were marked by feces is not formed and or lose weight, dead and sick during the treatment period, rats throughout the study would not eat. Rats drop out if match with exclusion criteria and replaced with other rats in accordance with the inclusion criteria, in order to get the number of rats in accordance with the sample.

PsP made by Sahabat Lingkungan Hidup Surabaya, a biopharmaceutical company. PsP extracted from mycelia of Ganoderma lucidum. PsP is prepared in dry powder form.

A total of 25 rats acclimated with normal food. Then the rats were fed with HFD to make a rat model of atherosclerosis, whereas rats for the control group were given a normal food. After being fed with high fat diet for 8 weeks, the rats were divided randomly into 5 groups: negative control group with normal diet plus saline solution as a placebo, a positive control group with HFD (atherosclerosis)+saline solution as a placebo, then the group treated with HFD plus saline containing 50, 150, 300mg/kg PsP for 5 weeks each group consisted of 5 rats. Diets are made every day given as a daily diet of 50g/rat/day. Diet gave at the same time during the day at 12.00-14.00. A normal feed consisting of chicken feed / Pars (with water content, protein, fat, fiber, ash, Ca, phosphorus, antibiotic, coccidiostat) 66.6 % and 33.4% wheat flour.

Measurement of IL-6, IL-10, TNF-α, hsCRP, MDA, SOD, lipid profile and foam cells in experimental animals by taking blood or organs of experimental animals. We measured Inflammation marker (IL-6, IL-10, TNF-α, hsCRP), Oxydative Stress marker (MDA, SOD) with ELISA kits and foam cell measurements with hematoxylin or HE.

Statistical Analysis

The data were analyzed with the SPSS version 7.0 software. Descriptive analysis that will be presented include the mean value, standard deviation, the lower and upper 95% confidence interval, and the minimum value of the maximum temptation. Bivariat analysis using Oneway Anova was used to identify significant difference between at least the two treatment groups in all parameters. Post Hoc Test Duncan test will be done if one way anova showed significant difference (p < 0.005) between at least two treatment groups to identify doses of PsP that affects the parameters.

Results

This study was conducted to determine the effect of Poly-saccharides Peptide (PsP) in inhibiting the formation of atherosclerosis in atherosclerosis rats induced by HFD. The mechanism of inhibition of the formation of atherosclerosis identified by identifying the parameters as follows: MDA, SOD (Oxidative Stress marker) IL-6, hsCRP, TNF-α, IL-10 (Inflammation Marker), Total Cholesterol, Triglycerides, Low Density Lipid (LDL), High Density Lipid (HDL) (Lipid Profile), and foam cell.

Oxidative Stress Marker

Lowest MDA levels were observed in the normal group. While the highest MDA levels found in atherosclerotic group, Descriptively, an increase dose of the PSP having an inclination to reduce levels of MDA. PsP at dose 300 mgkgBW significantly lowered MDA level (p= 0.001) (Tabel 1).

PsP showed no correlation with level of SOD descriptively and also of bivariate analysis (p = 0.280). Lowest SOD observed in the experimental results are in atherosclerosis group+PSP 50 mg. While the highest levels of SOD found in the atherosclerotic group + PSP 150 mg.

Inflammation Marker

IL-6 level were descriptively reduced with PsP dose 150 mg/kgBW, the lowest experimental results are in atherosclerosis group + PSP 150 mg. Bivariate analysis PsP has no correlation with IL-6 level (p=0.933).

PsP showed significantly reduced of hsCRp (p=0,018) in the treatment groups especially in dose 50 mg/kgBW (Tabel 1).

TNF-α and IL-10 levels were not correlated with PsP treatment (p=0.894 and p=0.98 respectively).

Table 1: Results of MDA, SOD, IL-6, , IL-10, TNF- α, Total Cholesterol, LDL, Triglyceride, HDL and Foam Cell. 

Negative

Control

Positive

Control

Athero + PsP 50 Athero + PsP 150 Athero + PsP 300 One-Way Anova
Mean + SD Min – Max Mean + SD Min – Max Mean + SD Min – Max Mean + SD Min – Max Mean + SD Min – Max Sig
MDA 12.7 + 3.7 6.5 – 15.7 41.4 + 12.6 28.5 – 62.0 28.3 + 11.0 12.3 – 37.7 26.6 + 6.8 17.8 – 33.3 20.3 + 9.3 13.0 – 36.5 0.001
SOD 1.2 + 0.3 1.0 – 1.6 3.0  + 1.9 0.7 – 5.0 1.9 + 1.7 0.7 – 4.8 3.8 + 1.7 2.4 – 6.1 3.1 + 3.3 0.8 – 8.9 0.280
IL-6 1007.2 + 94.6 913.4 – 1165.4 1322.8 + 545.0 549.5 – 1934.3 1198.1 + 368.9 690.3 – 1686.7 957.1 + 108.7 853.0 – 1132.6 1039.8 + 158.3 807.6 – 1213.7 0.933
hsCRP 841.6 + 400.6 226.6 – 1326.6 3141.6 + 462.9 2566.6 – 3606.6 1822.6 + 1051.4 366.6 – 2726.6 2246.6 + 688.2 1286.6 – 2886.6 2318.6 + 1625.2 546.6 – 4146.6 0.018
TNF-α 78.9 + 11.7 60.2 – 90.6 117.2 + 33.1 79.0 – 169.7 120.1 + 127.5 8.5 – 281.9 134.6 + 138.9 4.0 – 324.2 120.0 + 59.7 29.0 – 176.1 0.894
IL-10 127.4 + 11.7 107.3 – 150.4 202.5 + 73.3 134.9 – 311.9 131.7 + 45.2 68.7 – 187.1 120.1 + 51.5 68.7 – 206.5 103.6 + 13.6 80.8 – 116.8 0.027
Cholesterol 47.2 + 10.0 37.0 – 61.0 82.8 + 10.8 68.0 – 95.0 81.8 + 10.3 73.0 – 99.0 6.9 + 6.9 54.0 – 71.0 76.0 + 10.1 63.0 – 89.0 0.000
LDL 13.2 + 6.5 7.1 – 21.2 31.0 + 18.5 7.9 – 46.6 26.7 + 8.5 16.1 – 39.3 21.9 + 12.9 6.1 – 35.5 23.4 + 15.7 5.9 – 47.4 0.129
Tryglycerides 76.2 + 24.7 42.0 – 106.0 12.4 + 69.3 63.0 – 232.0 138.2 + 57.7 56.0 – 203.0 126.2 + 61.7 68.0 – 196.0 154.6 + 72.8 76.0 – 273.0 0.340
HDL 21.7+ 5.6 16.4 – 31.1 21.3+ 4.0 18.7 – 28.3 22.9+ 3.1 18.6 – 27.4 27.4+ 4.4 22.5 – 33.5 68.1 + 78.8 29.0 – 209.0 0.02
Foam cell 11.0 + 24.6 0.0 – 55.0 52.0 + 40.2 16.0 – 102.0 45.6 + 17.8 30.0 – 105.0 21.8 + 10.9 12.0 – 40.0 7.0 + 13.0 7.0 – 13.0 0.024

 

Lipid Profile

PsP treatment decreased cholesterol total level (Tabel 1) and increased HDL level significantly (p=0.04 and p=0.002 respectively) at PsP dose 50,150,300 mg/kgBW, but there is no correlation with LDL and triglyceride level (p=0.129 and p=0.340).

Foam Cell

PsP decreased foam cell count significantly (p=0.024) at PsP dose 300 mg/kgBW (Tabel 1). Based on these results to high reduction in MDA Level achieved was 300 mg/KgBW PsP and to high reduction in hsCRP achieved was 50 mg/KgBW PsP.

Figure 1 Figure 1: Foam cell in histopathology of aorta stained with hematoxylin observed with 40x magnification (A) Negative control group. (B) Positive control group (c) atherosclerotic model with high-fat diet + PsP 50 mg /kgBB (D) atherosclerotic model with high-fat diet + PsP 150 mg /kgBB (E) atherosclerotic model with high-fat diet + PsP 300 mg /kgBB

Click here to View figure

 

This study also showed that the PsP could correct lipid profiles and reduce the levels of foam cells. To get the required reduction in total cholesterol need PSP 150mg/kgBW or 300mg/kgBW, while to be able to increase HDL can use 50mg/kgBW dose, 150mg/kgBW or 300mg/kgBW. As for lowering the number of foam cells near to normal requires a PsP with 300mg/kgBB dose.

Discussion

Ganoderma lucidum has been used since hundreds of years ago in various countries in the world, but the effectiveness and side effects is still in ongoing research. Limited study focus in the effect of Ganoderma lucidum in atherogenesis especially in chronic inflammation, to our knowledge, we conduct the first in this field.

In the study, presented MDA level showed atherosclerotic rats given PSP 300mg/kgBW group was significantly different to the normal rats. Interestingly in our research PsP can’t increase significantly SOD level (p=0.280) although PsP treatment at dose  150mg/kgBW gave the highest effect in increasing SOD, which means higher than normal and atherosclerosis groups. It shows that treatment of PsP can be used as anti oxidant to reduce oxidative stress, although statistically SOD not significantly increased. This result is consistent with previous studies. Galor et al, in 2004 in healthy individuals given showed no significant difference in MDA levels between the placebo and treatment groups (Wachtel-Galor S, et al, 2004). PsP can increase antioxidant defense systems by increasing the activity of SOD in the body which are composed of antioxidant enzymes that play a role of antioxidant nutrients to protect from oxidative stress. In principle antioxidant enzymes including SOD, GPX and CAT, SOD which catalyzes dysmutase superoxide into oxygen and hydrogen peroxidation (Zhonghui Z, et al, 2013; Pan D, et al, 2013; Oluba OM, et al, 2010).

There were conflicting result in our study in inflammation marker. Descriptively, giving 150mg PSP can reduce levels of IL-6 and lower levels of IL-6 than atherosclerosis rats. And there are significant differences in the levels of inflammatory cytokines hsCRP between the negative control group, atherosclerosis, and thetreatment group were treated with PsP. In the group treated with a dose of 50mg PsP turns hsCRP levels of hsCRP levels nearly equivalent to the negative control group, whereas if the dose is increased to 150mg or 300mg not further lower hsCRP levels. But PsP administration seems has no role in affecting level of TNF-α and IL-10. Since IL-10 is an anti inflammation marker, our study showed reversed result, whereas normal rat has higher IL-10 level than treatment group.

Previous studies also reveals conflicting result. Galor research, at 2004 in healthy individuals no significant difference in hsCRP levels between the placebo and treatment groups (Wachtel-Galor S, et al, 2004). Li’s research in 2007, in a population of patients suffering from rheumatoid arthritis (RA) with disease-modifying antirheumatic therapy drugs (DMARDs) eg hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide, also showed no difference CRP level between placebo groups were given additional therapy extract ganoderma 4 g in combination with other herbs for the treatment of 24 weeks(Li F, et al, 2011). Several studies also show different result in different design. Ganoderma lucidum increases IL-10 level (Lin YL, et al, 2005; Sun, 2011; Futrakul, 2004) increases TNF-α (Cui, 2012) and no correlation with IL-6 level in cancer patients(Gao, 2005). But none of the previous studies focus on inflammatory aspect of atherosclerosis.

In this study, usage of PsP in rats with high fat diet the lipid profile. Blood cholesterol and HDL levels found statistically significant differences (p=0.04 and p=0.02 respectively) between treatment groups by titration doses of PsP 50, 150 and 300 mg/kgBW. Li, 2011 on research with rats model of streptozotocin-induced diabetes mellitus also shows the effect antihyperglikemia and anticholesterol-emia( Li F, et al, 2011). These results are in contrast to studies of Seto, et al 2009 in obese diabetic rats models + db / + db Ganoderma lucidum treated for 4 weeks, did not give the effect of anti- dyslipidemia, lipid profile does not improve after administration of Ganoderma lucidum (Seto SW, et al, 2009).

Atherogenesis is clearly inhibited with PsP treatment. Foam cell, results of chronic inflammation and oxidative stress decreased significantly (p=0.000). Giving PSP with increasing doses with optimum dose 300 mg/kgBB tend to be followed by a decline seen the average number of Foam Cell. This result sthrengtens study by You and Lin in 2002, showed that Ganoderma lucidum polysaccharides peptide can inhibit foam cell formation and necrosis of macrophages(You YH, et al, 2002).

Limitation of this study is conflicting results especially in marker of inflammation probably due to short time (5 weeks) of treatment of PsP, whereas other studies usually used at least 8 weeks of treatment(Meng G, et al, 2011). Also, PsP administration given at 9th week, after 8 weeks rats fed with HFD, means chronic inflammation and oxidative stress is longer than treatment given. Probably that PsP is more useful as prevention than treatment.

Conclusion

PsP administration at dose 50,150,300 mg/kgBW is a promising prevention or treatment as anti inflammation and anti oxidant thus inhibiting atherogenesis in CAD.

Further research is needed to evaluate safety and efficacy of PsP in human by conducting toxicity and cohort study.

Acknowledgements

We acknowledge the Sahabat Lingkungan Hidup Surabaya for preparing the PsP extract of Ganoderma lucidum.  And this study was funded by Directorat of High Education through Brawijaya University Indonesia.

Reference

  1. Go AS, Mozaffarian D, Roger VL, Emelia J. Benjamin, Berry JD, Blaha MJ. Heart Disease and Stroke Statistics—2014 Update. Circulation Journal. 2013;129(e28-e292).
  2. Sprague A, Khalil R. Inflammatory Cytokines in Vascular Dysfunction and Vascular Disease. Biochem Pharmacol. 2009;78(6):539 – 52.
  3. Yihuai G, Chen G, Xihu D, Jingxian Y, Shufeng Z. A Phase I/II Study of Ling Zhi Ganoderma lucidum (W Curt.: fr.) lloyid (Aphyllophoromycetideae) extract in patients with coronary heart disease. International Journal of Medicinal mushrooms. 2004;6:327 – 34.
  4. Xu Z, Chen X, Zhong Z, Chen L, all e. Ganoderma lucidum polysaccharides : immunomodulation and potential anti-tumor activities. Am J Chin Med. 2011;39(1):15 – 27.
  5. Wachtel-Galor S, Tomlinson B, Benzie IFF. Ganoderma lucidum (‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation study. British Journal of Nutrition. 2004;91:263 – 9.
  6. Zhonghui Z, Xiaowei Z, Fang F. Ganoderma lucidum polysaccharides supplementation attenuates exercise-induced oxidative stress in skeletal muscle of mice. Saudi Journal of Biological Sciences. 2013.
  7. Pan D, Zhang D, Wu J, Chen C, Xu Z. Antidiabetic, Antihyperlipidemic and Antioxidant Activities of a Novel Proteoglycan from Ganoderm Lucidum Fruiting Bodies on db/db Mice and the Possible Mechanism. PLoS ONE. 2013;8(7):e68332.
  8. Oluba OM, Onyeneke EC, Ojieh GC, Idonije BO, Ojiezeh TI. Hepatoprotective Potential of Aqueous Extract of Ganoderma lucidum Against Carbon Tetrachloride Intoxication in Rats. Der Pharmacia Lettre. 2010;2(4):432-9.
  9. Li F, Zhang Y, Zhong Z. Antihyperglycemic Effect of Ganoderma lucidum Polysaccharides on Streptozotocin-Induced Diabetic Mice. Int J Mol Sci. 2011;12:6135-45.
  10. Lin YL, Liang YC, Lee SS, Chiang BL. Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-B and p38 mitogen-activated protein kinase pathways. Journal of Leukocyte Biology. 2005:78.
  11. Sun LX. Ganoderma lucidum polysaccharides antagonize the suppression on lymphocytes induced by culture supernatants of B16F10 melanoma cells. J Pharm Pharmacol. 2011;63(5):725-35.
  12. Futrakul N. Ganoderma lucidum suppresses endothelial cell cytotoxicity and proteinuria in persistent proteinuric focal segmental glomerulosclerosis (FSGS) nephrosis. Clin Hemorheol Microcirc. 2004;31(4):267-72.
  13. Cui XY. Extract of Ganoderma lucidum prolongs sleep time in rats. J Ethnopharmacol. 2012;139(3):796-800.
  14. Gao Y. Effects of Water-Soluble Ganoderma lucidum Polysaccharides on the Immune Functions of Patients with Advanced Lung Cancer. Journal of Medicinal Food. 2005;8(2):159-68.
  15. Seto SW, Lam TY, Tam HL, Au AL, Chan SW, Wu JH, et al. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2009;16(5):426-36.
  16. You YH, Lin ZB. Protective effects of Ganoderma lucidum polysaccharides peptide on injury of macrophages induced by reactive oxygen species. Acta pharmacologica Sinica. 2002;23(9):787-91.
  17. Meng G, Zhu H, Yang S, Wu F, Zheng H, Chen E, et al. Attenuating effects of Ganoderma lucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. Carbohydrate Polymers. 2011;84(1):180-5.
(Visited 327 times, 1 visits today)